Sangamo Historical Balance Sheet

SGMO Stock

USD 2.35 0.47 16.67%

Trend analysis of Sangamo Therapeutics balance sheet accounts such as Liabilities And Stockholders Equity of 218.1 M, Other Stockholder Equity of 1.6 B, Total Liabilities of 73.5 M or Short Long Term Debt Total of 30 M provides information on Sangamo Therapeutics' total assets, liabilities, and equity, which is the actual value of Sangamo Therapeutics to its prevalent stockholders. By breaking down trends over time using Sangamo Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Sangamo Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sangamo Therapeutics is a good buy for the upcoming year.

Sangamo Therapeutics Inventory

0.95

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.

About Sangamo Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Sangamo Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Sangamo Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Sangamo Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Sangamo currently owns. An asset can also be divided into two categories, current and non-current.

Sangamo Therapeutics Balance Sheet Chart

At this time, Sangamo Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 19th of December 2024, Non Current Liabilities Total is likely to grow to about 57.7 M, though Retained Earnings are likely to grow to (1.3 B).

Total Assets Total Stockholder Equity Other Assets Common Stock Shares Outstanding

Add Fundamental

Total Assets

Total assets refers to the total amount of Sangamo Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Sangamo Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most accounts from Sangamo Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Sangamo Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.At this time, Sangamo Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 19th of December 2024, Non Current Liabilities Total is likely to grow to about 57.7 M, though Retained Earnings are likely to grow to (1.3 B).

	2021	2022	2023	2024 (projected)
Total Stockholder Equity	375.3M	295.0M	82.9M	144.6M
Total Assets	721.9M	562.5M	165.3M	218.1M

Total Stockholder Equity Total Assets

Sangamo Therapeutics balance sheet Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Net Debt	Other Current Assets	Property Plant Equipment
Total Assets		0.97	-0.4	0.89	0.53	0.63	0.97	0.8	0.79	0.95	0.91	0.42	0.89	0.94	0.32	0.96	0.41	0.06	0.89	0.97	0.75	0.97	0.03	-0.78	0.7	0.51
Total Stockholder Equity	0.97		-0.31	0.81	0.46	0.56	0.89	0.73	0.7	0.86	0.84	0.32	0.83	0.88	0.21	0.96	0.54	-0.06	0.91	0.9	0.65	0.97	-0.1	-0.74	0.56	0.42
Retained Earnings	-0.4	-0.31		-0.41	-0.98	-0.96	-0.48	-0.79	-0.38	-0.56	-0.6	-0.87	-0.46	-0.51	-0.96	-0.22	0.0	-0.13	-0.11	-0.45	-0.84	-0.32	-0.22	0.19	-0.7	-0.86
Other Assets	0.89	0.81	-0.41		0.49	0.58	0.92	0.8	0.64	0.93	0.94	0.52	0.83	0.95	0.33	0.79	0.31	0.23	0.69	0.9	0.8	0.79	0.19	-0.72	0.86	0.46
Common Stock Shares Outstanding	0.53	0.46	-0.98	0.49		0.99	0.58	0.84	0.47	0.65	0.67	0.86	0.56	0.61	0.93	0.37	0.08	0.06	0.26	0.56	0.88	0.46	0.14	-0.29	0.73	0.86
Other Stockholder Equity	0.63	0.56	-0.96	0.58	0.99		0.66	0.89	0.52	0.73	0.76	0.85	0.64	0.69	0.9	0.46	0.15	0.09	0.35	0.64	0.92	0.55	0.16	-0.37	0.77	0.87
Total Liab	0.97	0.89	-0.48	0.92	0.58	0.66		0.84	0.83	0.99	0.93	0.51	0.89	0.95	0.42	0.92	0.26	0.18	0.82	1.0	0.81	0.92	0.16	-0.78	0.81	0.57
Short Long Term Debt Total	0.8	0.73	-0.79	0.8	0.84	0.89	0.84		0.61	0.88	0.93	0.69	0.78	0.87	0.75	0.65	0.35	0.22	0.54	0.82	0.96	0.71	0.25	-0.53	0.79	0.8
Other Current Liab	0.79	0.7	-0.38	0.64	0.47	0.52	0.83	0.61		0.8	0.66	0.44	0.61	0.66	0.36	0.81	0.06	0.16	0.83	0.85	0.56	0.82	0.16	-0.51	0.59	0.41
Total Current Liabilities	0.95	0.86	-0.56	0.93	0.65	0.73	0.99	0.88	0.8		0.95	0.59	0.9	0.96	0.5	0.88	0.22	0.18	0.77	0.97	0.86	0.88	0.17	-0.77	0.86	0.63
Property Plant And Equipment Net	0.91	0.84	-0.6	0.94	0.67	0.76	0.93	0.93	0.66	0.95		0.61	0.87	0.97	0.53	0.78	0.39	0.24	0.66	0.91	0.92	0.8	0.23	-0.69	0.84	0.67
Accounts Payable	0.42	0.32	-0.87	0.52	0.86	0.85	0.51	0.69	0.44	0.59	0.61		0.39	0.56	0.82	0.23	-0.02	0.22	0.15	0.48	0.81	0.31	0.28	-0.15	0.81	0.69
Cash	0.89	0.83	-0.46	0.83	0.56	0.64	0.89	0.78	0.61	0.9	0.87	0.39		0.88	0.41	0.83	0.17	0.08	0.67	0.88	0.76	0.83	0.07	-0.94	0.73	0.62
Non Current Assets Total	0.94	0.88	-0.51	0.95	0.61	0.69	0.95	0.87	0.66	0.96	0.97	0.56	0.88		0.44	0.83	0.4	0.2	0.7	0.94	0.87	0.84	0.18	-0.74	0.83	0.58
Non Currrent Assets Other	0.32	0.21	-0.96	0.33	0.93	0.9	0.42	0.75	0.36	0.5	0.53	0.82	0.41	0.44		0.14	-0.13	0.3	0.03	0.41	0.81	0.24	0.4	-0.14	0.65	0.9
Cash And Short Term Investments	0.96	0.96	-0.22	0.79	0.37	0.46	0.92	0.65	0.81	0.88	0.78	0.23	0.83	0.83	0.14		0.37	-0.05	0.96	0.92	0.56	0.98	-0.09	-0.78	0.55	0.33
Net Receivables	0.41	0.54	0.0	0.31	0.08	0.15	0.26	0.35	0.06	0.22	0.39	-0.02	0.17	0.4	-0.13	0.37		-0.1	0.41	0.27	0.23	0.39	-0.13	-0.06	-0.02	-0.04
Common Stock Total Equity	0.06	-0.06	-0.13	0.23	0.06	0.09	0.18	0.22	0.16	0.18	0.24	0.22	0.08	0.2	0.3	-0.05	-0.1		-0.09	0.19	0.3	-0.02	0.99	-0.03	0.31	0.24
Short Term Investments	0.89	0.91	-0.11	0.69	0.26	0.35	0.82	0.54	0.83	0.77	0.66	0.15	0.67	0.7	0.03	0.96	0.41	-0.09		0.83	0.42	0.95	-0.14	-0.62	0.4	0.23
Non Current Liabilities Total	0.97	0.9	-0.45	0.9	0.56	0.64	1.0	0.82	0.85	0.97	0.91	0.48	0.88	0.94	0.41	0.92	0.27	0.19	0.83		0.79	0.93	0.16	-0.77	0.78	0.55
Property Plant And Equipment Gross	0.75	0.65	-0.84	0.8	0.88	0.92	0.81	0.96	0.56	0.86	0.92	0.81	0.76	0.87	0.81	0.56	0.23	0.3	0.42	0.79		0.63	0.34	-0.53	0.89	0.84
Total Current Assets	0.97	0.97	-0.32	0.79	0.46	0.55	0.92	0.71	0.82	0.88	0.8	0.31	0.83	0.84	0.24	0.98	0.39	-0.02	0.95	0.93	0.63		-0.05	-0.75	0.57	0.44
Common Stock	0.03	-0.1	-0.22	0.19	0.14	0.16	0.16	0.25	0.16	0.17	0.23	0.28	0.07	0.18	0.4	-0.09	-0.13	0.99	-0.14	0.16	0.34	-0.05		0.01	0.32	0.31
Net Debt	-0.78	-0.74	0.19	-0.72	-0.29	-0.37	-0.78	-0.53	-0.51	-0.77	-0.69	-0.15	-0.94	-0.74	-0.14	-0.78	-0.06	-0.03	-0.62	-0.77	-0.53	-0.75	0.01		-0.57	-0.4
Other Current Assets	0.7	0.56	-0.7	0.86	0.73	0.77	0.81	0.79	0.59	0.86	0.84	0.81	0.73	0.83	0.65	0.55	-0.02	0.31	0.4	0.78	0.89	0.57	0.32	-0.57		0.63
Property Plant Equipment	0.51	0.42	-0.86	0.46	0.86	0.87	0.57	0.8	0.41	0.63	0.67	0.69	0.62	0.58	0.9	0.33	-0.04	0.24	0.23	0.55	0.84	0.44	0.31	-0.4	0.63

Click cells to compare fundamentals

Sangamo Therapeutics Account Relationship Matchups

Sangamo Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	637.5M	938.6M	721.9M	562.5M	165.3M	218.1M
Total Stockholder Equity	432.7M	497.4M	375.3M	295.0M	82.9M	144.6M
Retained Earnings	(657.0M)	(778.0M)	(956.3M)	(1.1B)	(1.4B)	(1.3B)
Other Assets	10.6M	15.1M	16.8M	18.5M	1.0	0.95
Common Stock Shares Outstanding	112.1M	134.4M	144.6M	154.3M	174.4M	183.2M
Liabilities And Stockholders Equity	637.5M	938.6M	721.9M	562.5M	165.3M	218.1M
Other Stockholder Equity	1.1B	1.3B	1.3B	1.5B	1.5B	1.6B
Total Liab	204.8M	441.2M	346.6M	267.6M	82.4M	73.5M
Short Long Term Debt Total	44.4M	42.1M	48.1M	43.1M	38.1M	30.0M
Other Current Liab	21.3M	127.3M	28.4M	33.4M	27.9M	14.0M
Total Current Liabilities	69.9M	143.5M	127.9M	111.7M	47.7M	34.0M
Property Plant And Equipment Net	107.2M	112.4M	124.7M	125.5M	52.9M	29.2M
Accounts Payable	6.7M	12.6M	9.8M	22.4M	15.3M	16.0M
Cash	80.4M	131.3M	178.9M	100.4M	45.2M	45.0M
Non Current Assets Total	232.0M	278.9M	323.2M	262.2M	71.0M	68.1M
Non Currrent Assets Other	4.0M	7.9M	10.2M	12.3M	18.1M	19.0M
Cash And Short Term Investments	385.0M	692.0M	464.7M	277.6M	81.0M	77.0M
Net Receivables	37.6M	6.3M	6.4M	4.5M	1.3M	1.3M
Common Stock Total Equity	1.2M	1.4M	1.5M	1.7M	1.5M	1.4M
Short Term Investments	282.0M	510.1M	197.7M	177.2M	35.8M	34.0M
Non Current Liabilities Total	134.9M	297.6M	218.7M	155.8M	34.7M	57.7M
Property Plant And Equipment Gross	107.2M	112.4M	149.7M	162.1M	103.9M	109.1M
Total Current Assets	405.5M	659.7M	398.8M	300.3M	94.3M	175.7M
Accumulated Other Comprehensive Income	(2.4M)	5.4M	(4.0M)	(8.4M)	(4.6M)	(4.4M)
Common Stock	1.2M	1.4M	1.5M	1.7M	1.8M	1.7M
Net Debt	(36.0M)	(89.2M)	(130.8M)	(57.3M)	(7.1M)	(7.5M)
Other Current Assets	5.4M	24.0M	31.7M	36.4M	12M	12.6M
Property Plant Equipment	29.9M	41.3M	51.5M	63.5M	73.1M	76.7M
Current Deferred Revenue	38.7M	96.6M	85.7M	51.8M	59.5M	62.5M
Intangible Assets	53.2M	58.1M	53.8M	50.7M	58.3M	61.3M
Other Liab	93.7M	259.2M	174.6M	116.9M	134.4M	141.1M
Net Tangible Assets	340.1M	397.3M	281.9M	206.7M	237.7M	227.0M
Retained Earnings Total Equity	(657.0M)	(778.0M)	(956.3M)	(1.1B)	(1.0B)	(982.0M)
Capital Surpluse	1.1B	1.3B	1.3B	1.5B	1.7B	873.1M
Inventory	(22.5M)	(50.5M)	(88.2M)	1.0	0.9	0.95
Deferred Long Term Liab	6.6M	7.2M	6.6M	6.3M	7.2M	9.3M

Pair Trading with Sangamo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangamo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Sangamo Stock

0.84	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.79	LLY	Eli Lilly	Pair Corr
0.76	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.72	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.67	VALN	Valneva SE ADR	Pair Corr

The ability to find closely correlated positions to Sangamo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangamo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangamo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangamo Therapeutics to buy it.

The correlation of Sangamo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangamo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangamo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Sangamo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:

How To Invest In Sangamo

Details

Is Sangamo Stock a good investment?

Details

What is Sangamo Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.

You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.24)

Revenue Per Share

0.066

Quarterly Revenue Growth

(0.95)

Return On Assets

(0.58)

Return On Equity

(1.94)

The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sangamo Historical Balance Sheet

Sangamo Therapeutics Inventory

0.95

About Sangamo Balance Sheet Analysis

Sangamo Therapeutics Balance Sheet Chart

Total Assets

Total Stockholder Equity

Common Stock Shares Outstanding

Sangamo Therapeutics balance sheet Correlations

Sangamo Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sangamo Therapeutics balance sheet Accounts

Pair Trading with Sangamo Therapeutics

Moving against Sangamo Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Total Liab
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Total Current Liabilities	+ 0.99	Total Liab
Common Stock	+ 0.99	Common Stock Total Equity
Total Current Assets	+ 0.98	Cash And Short Term Investments
Total Stockholder Equity	+ 0.97	Total Assets

Common Stock Shares Outstanding	- 0.98	Retained Earnings
Non Currrent Assets Other	- 0.96	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Net Debt	- 0.94	Cash
Accounts Payable	- 0.87	Retained Earnings
Property Plant Equipment	- 0.86	Retained Earnings